BIOVIE INC. (BIVIW)

Quarterly Report Filed: 2026-05-11

The filing is dated 2026-05-11 for Q3 fiscal year ending 2026-03-31, indicating BioVie is reporting on a nine-month period (2025-07-01 to 2026-03-31), suggesting potential fiscal year restructuring or extended reporting period.
The document structure shows extensive tracking of equity instruments including common stock, warrants, stock options, and RSUs across multiple reporting periods, indicating significant equity-based compensation activity and potential dilution considerations.
The presence of a Long COVID Program as a tracked segment suggests this is a material business focus area, with specific financial tracking from 2024-2026, indicating ongoing clinical or commercial development in this therapeutic area.

Quarterly Report Filed: 2026-02-06

The company reported a significant increase in cash and short-term investments, indicating strong liquidity and the ability to fund ongoing operations.
The company has been actively granting stock options and restricted stock units to its employees, suggesting a focus on retaining and incentivizing key talent.
The company appears to have made some recent changes to its warrant agreements, which may impact the dilution of existing shareholders.

Insider Trading Filed: 2026-01-09

James Lang, a director of BioVie Inc., acquired 420,500 stock options at an exercise price of $1.31 per share, vesting over the next 1-3 years.
The stock option grants indicate management's confidence in the company's future prospects and a desire to incentivize Lang's continued service as a director.
The vesting schedule of the options, with significant portions vesting immediately and over the next few years, suggests the company wants to retain Lang's expertise and involvement in the near to medium term.

Insider Trading Filed: 2026-01-09

Amy Suzon Chappell, a director of BioVie Inc. (BIVI), was granted 57,500 stock options on January 5, 2026 with a strike price of $1.31 and a 5-year vesting schedule.
The stock option grant indicates that Chappell is taking a long-term view on the company's prospects, as the options will vest over several years.
Insider ownership and alignment with shareholders is a positive sign for BioVie's future growth and development.

Insider Trading Filed: 2026-01-09

Kameel Farag, a director of BioVie Inc., acquired 57,500 stock options with an exercise price of $1.31, vesting over time. This suggests the director is bullish on the company's prospects and willing to invest more in the stock.
The stock option grant was awarded on January 5, 2026, indicating recent management confidence in the company's future performance.
With the director now holding 57,500 stock options, their total beneficial ownership in the company has increased, aligning their interests with those of other shareholders.

Insider Trading Filed: 2026-01-09

The reporting person, Michael Edward Sherman, acquired 80,000 stock options and 341,100 stock options on January 5, 2026, indicating a significant increase in his insider ownership of the company.
The stock options have a 5-year vesting period, suggesting a long-term investment commitment by the reporting person.
The exercise price of the stock options is $1.31, which is relatively low compared to the current market price, potentially providing the reporting person with a favorable entry point.

Insider Trading Filed: 2026-01-09

Cuong V. Do, President and CEO of BioVie Inc., acquired 665,300 stock options on January 5, 2026 with a strike price of $1.31 and a 10-year expiration. This suggests the CEO is confident in the company's future prospects.
The options vest over a 4-year period, with 55% vesting immediately and the remainder vesting in three equal installments over the next 3 years. This aligns the CEO's incentives with long-term shareholder value creation.
The options are held indirectly through Do & Rickles Investments LLC, which may indicate estate or tax planning considerations behind the insider transaction.

Insider Trading Filed: 2026-01-09

Sigmund Rogich, a director of BioVie Inc., acquired 211,100 stock options with an exercise price of $1.31, which indicates potential insider confidence in the company's prospects.
The options granted to Rogich have a 5-year term and vest over different schedules, suggesting a long-term investment horizon.
The form 4 filing suggests that BioVie's management is aligning the interests of directors with those of shareholders through equity-based incentive compensation.

Insider Trading Filed: 2026-01-09

Joanne Wendy Kim, the Chief Financial Officer, has been granted 110,100 stock options at an exercise price of $1.31. This represents a significant insider acquisition, potentially signaling management's confidence in the company's future prospects.
The options vest over a 4-year period, with 55% vesting immediately and the remaining 45% vesting in three equal installments over the next three years. This vesting schedule aligns the CFO's incentives with long-term shareholder value creation.
The large size of the option grant, coupled with the gradual vesting schedule, suggests that the company is investing in its leadership team and seeking to retain key talent over the long-term.

Insider Trading Filed: 2026-01-09

Joseph M. Palumbo, the Chief Medical Officer of BioVie Inc. (BIVI), has been granted 132,000 stock options with an exercise price of $1.31 per share. This indicates potential insider confidence in the company's future prospects.
The options will vest over a 4-year period, with 55% vesting immediately and the remaining 45% vesting in 3 equal installments over the next 3 years. This long-term vesting structure aligns the executive's interests with those of the company and its shareholders.
The significant number of options granted, as well as the multi-year vesting period, suggest that BioVie Inc. views Palumbo as a key executive whose long-term performance is expected to contribute to the company's success.

Important Information